Understanding the potential profile of adverse events associated with cancer treatment is essential in balancing safety versus benefits. Multiple stakeholders make use of this information for decision making, including patients, clinicians, researchers, regulators, and payors. Currently, adverse events are reported by clinical research staff, yet evidence suggests that this may contribute to underreporting of symptom events. Direct patient reporting via electronic interfaces offers a promising mechanism to enhance the efficiency and precision of our current approach and may complement clinician reports of adverse events. The National Cancer Institute has contracted to develop and test an item bank and software system for directly eliciting adverse symptom event information from patients in cancer clinical research, called the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events. The validity, usability, and scalability of the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events prototype are currently being examined in academic and community-based settings.
Limitations of drug safety monitoring in both the preapproval and postmarket settings are widely acknowledged. 1 From an informatics perspective, these limitations are related to the quality of information collected, as well as to processes for efficient collection, aggregation, and analysis of these data, and methods of communication to stakeholdersVincluding patients, clinicians, regulators, and payors. 2, 3 Information about adverse events in oncology is typically derived from prospective clinical trials conducted in the regulatory setting toward obtaining drug approval, as well as from postmarket studies (or in rare cases, case reports or voluntary reporting via mechanisms like the U.S. Food and Drug Admin-istration's [FDA's] Adverse Event Reporting System). Postmarket studies may be conducted as part of an industry sponsor's postmarket regulatory obligation to the U.S. FDA or may be conducted by independent investigators and organizations outside this framework (such as in the U.S. National Cancer Institute's [NCI's] cooperative groups).
U.S. drug labels include adverse event information, which is largely derived from research conducted by sponsors in the regulatory context and filtered by sponsors and regulators based on frequency and severity of these events. It is common for oncology drug labels to list 50 to 100 individual adverse reactions, which is comparable to labels in other diseases (Table 1 ). This number of adverse effects is often overwhelming to patients trying to determine what experience they are likely to have with a particular treatment. 4 In the United States, drug labels are currently being redesigned, in part because of recognition that greater clarity about adverse reactions is needed.
ADVERSE EVENT REPORTING IN COMPARATIVE EFFECTIVENESS RESEARCH
In the largely nonregulated space of comparative effectiveness research (CER), the level of precision with which adverse events are collected and reported is inconsistent. Notwithstanding institutional review board oversight and traditional mechanisms for monitoring safety data in CER studies that involve patients, standards for how adverse event information is reported both to institutional review boards and in publications vary widely. Information about product safety derived from CER studies conducted by independent investigators generally is not incorporated into drug labels for the products being evaluated. Therefore, patients, clinicians, and third-party aggregators of clinical infor-mationVsuch as drug information databases, compendia, or developers of systematic reviews, clinical practice guidelines, and decision-support toolsVare left to pool and weight data about safety and tolerability from disparate sources.
In the context of CER, in which studies are intended to reflect the balance between risks and benefits in real-world settings with patients as the key stakeholders, one would expect substantial attention to be paid to the safety of interventions under evaluation. Moreover, assessment of the comparative tolerability of products is an essential component of CER and depends on the fidelity of safety reporting. The recent U.S. Patient Protection and Affordable Care Act created an independent organization to identify methodological standards in CER, called the Patient-Centered Outcomes Research Institute. An area of focus that has been discussed at public meetings of Patient-Centered Outcomes Research Institute is assessment of harms in CER.
ADVERSE EVENT REPORTING AND INFORMATICS
Despite acknowledged limitations in the assessment of adverse symptom events, there has been substantial progress in the standardization of adverse event reporting in general. MedDRA is a hierarchical lexicon of adverse event terms, which was created by an International Conference on Harmonisation, and is maintained across languages by the International Federation of Pharmaceutical Manufacturers and Associations. MedDRA is universally used in clinical trials in the regulatory context. In oncology, specifically, the NCI's CTCAE is the standard item bank used for adverse event reporting. Whereas MedDRA only includes terms for adverse events, the CTCAE includes specific criteria for grading the severities of adverse events. Adverse event terms used in the CTCAE were recently harmonized with MedDRA in its update to CTCAE version 4. Therefore, almost all cancer clinical trials report adverse events based on the same criteria, the CTCAE, with mapping of these terms to MedDRA.
REVIEW ARTICLE
In clinical trials sponsored by the NCI, 2 electronic systems have been used for centralized reporting of adverse events: the Adverse Event Expedited Reporting System and Clinical Data Update System. Both of these systems require reporting using CTCAE criteria.
Integration of adverse event reporting into electronic clinical trial management systems and electronic medical records is also increasingly common and, in the future, will allow for real-time monitoring of adverse events at the patient and group levels. Finally, efforts such as the FDA's SENTINEL initiative (www.fda.gov/Safety/FDAsSentinelInitiative/ucm2007250.htm) are underway to link databases that include adverse event data, including electronic health record systems, administrative and insurance claims databases, and registries towards developing active methods for post-market safety surveillance.
The overall goal of these efforts is to standardize terminologies and improve the efficiency of reporting and aggregating large amounts of adverse event information by harnessing technology. However, none of them address the limitations involved with primary data collection and documentation of patients'symptoms. Therefore, the information being standardized and aggregated is, by its nature, insufficient.
ADVERSE SYMPTOM EVENTS
About a third of adverse reactions listed in oncology drugs are symptoms (Table 1) . Capturing symptom data in clinical trials differs from other types of adverse event data (eg, laboratory tests) in that it depends on eliciting subjective information from patients. It is acknowledged that the current process in oncology clinical trials for eliciting adverse symptom event information from patients is inadequate. 5 Evidence indicates that the validity of reporting symptom outcomes is eroded when those reports are filtered through clinical staff. 6 Symptoms experienced by patients are often underestimated by clinical staff members who are responsible for eliciting and reporting this information (both in terms of frequency of occurrence and severity). 7 Staff-based adverse event reporting occurs at clinic visits, and thus, symptoms that occur between visits may be missed.
This presents a challenge from the informatics perspective. In order for an adverse symptom event to be documented in clinical research, the patient must first articulate the problem to a responsible clinical staff member. The staff member will then document that event, generally in a medical chart. This documentation may be on paper or electronic and generally does not involve use of a standardized valid measurement scale. Subsequently, this information is abstracted by a different staff member and converted to a standardized terminology, such as the Medical Dictionary for Regulatory Affairs (MedDRA) or the NCI Common Terminology Criteria for Adverse Events (CTCAE). During this process of information flow, the reported experience of the patient may be modified either because of interpretation by the clinical staff member (eg, ''Mrs. Jones doesn't look like she's in that much pain, she says severe, but I suspect it's mild'') or because of the process of mapping the reported experience to the standardized lexicon (''The medical chart says the patient is queasy, that probably means nausea in the CTCAE'').
ADVERSE EVENT REPORTING AND PATIENT-REPORTED OUTCOMES
Recently, standards for collecting information directly from patients in clinical trials have been consolidated in an FDA Guidance document. 8 These standards largely pertain to patientreported outcomes (PROs) that are intended to result in a labeling claim in the regulatory setting (eg, improved pain in metastatic prostate cancer) but have also been widely adopted outside the regulatory setting. The implication of these standards is that symptom experiences of patients should be reported by patients themselves, to minimize loss or transformation of this information. The patient knows his or her experience best and is in the best position to meaningfully report on it, without interpretation or modification by an observer. 9 However, the use of PROs has been largely restricted to collection of data to support the efficacy of products rather than their safety. While it is now common in clinical trials for specific symptoms or health-related quality of life domains to be assessed via patient self-report questionnaires to support assertions of product efficacy or effectiveness, adverse symptom events continue to be elicited, filtered, and reported by clinical staff members.
Direct patient reporting of this information has been proposed as an alternative approach that is more efficient and less prone to data loss, misinterpretation, or transformation. 2, 5 Patient reporting of symptoms is more reliable and valid than clinician reporting and is more highly correlated with measures of functional performance and health status than clinician reports. 6, 7, 10 Patient reporting better identifies baseline symptoms related to preexisting conditions, and patients are willing and able to self-report their own adverse symptom eventsVeven patients with end-stage disease and poor performance status. 10, 11 
NCI'S PRO-CTCAE INITIATIVE
Based on a recognition of the limitations of the cliniciancentric approach to adverse symptom event documentation in cancer trials, in 2008, the NCI contracted for the development of a patient-reported outcomes version of the CTCAE, called the PROCTCAE, and an accompanying software platform. 12 The scope of these two contracts, awarded to Memorial Sloan-Kettering Cancer Center, includes creating patient questionnaires that assess adverse symptom events; developing an electronic platform for administering these questionnaires to patients via Web or telephone (ie, interactive voice response system) and for reporting the data to clinicians and investigators; testing the measurement properties of PRO-CTCAE questions; and evaluating the feasibility of integrating this approach into multicenter clinical trials. To date, 124 items representing 78 discrete symptoms in the CTCAE have been developed in English and refined via a cognitive interviewing study in a diverse national sample. 13 A multisite validation study is ongoing in more than 1000 patients, 14 as well as a national usability testing evaluation of the software. 15 The items have been translated into Spanish and are undergoing linguistic validation; translations into additional languages are underway via Material Transfer Agreements established between the NCI and interested investigators. Moreover, feasibility studies are commencing within multicenter clinical trials in the NCI cooperative groups.
Functionality of the PRO-CTCAE software platform includes the ability for investigators to build and schedule electronic questionnaires for patient self-reporting ( Fig. 1) . Skip patterns to minimize respondent burden are integrated, and the software provides mechanism for patients to report additional symptoms beyond the PRO-CTCAE items, from an existing menu derived from MedDRA or as free text. Automated alerts are sent to clinical staff for missed reports or symptoms that exceed prespecified thresholds. Reports can show patient-level or study-level information in standardized graphical formats. The system was designed to be compatible with related software systems supported by the NCI for data capture and adverse event reporting in clinical research.
Following a rigorous development and evaluation process, the PRO-CTCAE has the potential to enhance the precision and validity of adverse event reporting. Streamlined with other AE reporting systems, the PRO-CTCAE will directly integrate the patients' perspectives as they relate to symptom experiences to inform toxicity grading. As a further benefit, this electronic platform will enable more rapid identification of problematic symptoms allowing clinicians to promptly respond and minimize future complications; ultimately improving the quality of care patients receive.
CONCLUSIONS
Electronic patient reporting systems, like the PRO-CTCAE, may improve the quality and comprehensiveness of cancer treatment safety information collected in clinical research. The model of reporting that will evolve in the future remains to be determined, but conceivably an approach in which directly reported patient information informs mandatory staff adverse event reporting could emerge. How this information should be used to optimize decision making and reporting of data in early phase and phase III trials is an area of active research sponsored by the NCI.
Beyond the clinical trial setting, patient-reported indices of safety and tolerability may play a role in longitudinal registries and safety surveillance systems. Moreover, there is increasing interest to integrate this information into routine cancer care. 16 Ultimately, the goals of this work were to develop information systems that allow the patient perspective to be better represented in clinical research and to develop therapies and care processes that are tailored to patient's preferences and will optimize therapeutic response.
